MBX Biosciences (MBX) Liabilities and Shareholders Equity (2023 - 2026)

MBX Biosciences has reported Liabilities and Shareholders Equity for 4 years, with the latest figure at $452.7 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 84.08% year-over-year to $452.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 84.4% YoY) and the FY2025 annual result came in at $385.1 million, up 43.42% from the prior year.
• Liabilities and Shareholders Equity advanced to $452.7 million in Q1 2026 per MBX's latest filing, from $385.1 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $452.7 million in Q1 2026 and troughed at $84.2 million in Q4 2023.
• A 4-year average of $293.8 million and a median of $275.5 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity jumped 219.0% in 2024, then soared 41.67% in 2025.
• Over 4 years, Liabilities and Shareholders Equity stood at $84.2 million in 2023, then surged by 219.0% to $268.5 million in 2024, then soared by 43.42% to $385.1 million in 2025, then rose by 17.54% to $452.7 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $452.7 million, $385.1 million, and $400.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.